66346-83-6

Basic information

• Product Name: 6-Chloropyridazine-3-carboxamide
• Synonyms: 6-Chloropyridazine-3-carboxamide;3-PyridazinecarboxaMide, 6-chloro-;3-Carbamoyl-6-chloropyridazine, 3-(Aminocarbonyl)-6-chloro-1,2-diazine;3-Chloro-pyridazine-6-carboxamide
• CAS NO: 66346-83-6
• Molecular Formula: C₅H₄ClN₃O
• Molecular Weight: 157.56
• Product Categories: Pyrazines, Pyrimidines & Pyridazines;Pyrazines, Pyrimidines & Pyridazines
• Mol File: 66346-83-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 424.641 °C at 760 mmHg
• Flash Point: 210.616 °C
• Appearance: /
• Density: 1.479 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.596
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6-Chloropyridazine-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloropyridazine-3-carboxamide(66346-83-6)
• EPA Substance Registry System: 6-Chloropyridazine-3-carboxamide(66346-83-6)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 66346-83-6(Hazardous Substances Data)

Usage

General Description

6-Chloropyridazine-3-carboxamide is a chemical compound with the molecular formula C5H3ClN4O. It is a derivative of pyridazine and belongs to the class of carboxamides. 6-Chloropyridazine-3-carboxamide is commonly used in organic synthesis and pharmaceutical research due to its potential biological and medicinal properties. It has been studied for its potential antitumor, antifungal, and antibacterial activities. Additionally, 6-Chloropyridazine-3-carboxamide has shown promise as an inhibitor of Janus kinase enzymes, which are implicated in various inflammatory and autoimmune diseases. Its unique molecular structure and diverse pharmacological properties make it an important target for further research and development in the field of medicinal chemistry.

InChI:InChI=1/C5H4ClN3O/c6-4-2-1-3(5(7)10)8-9-4/h1-2H,(H2,7,10)

Upstream product

• 98995-11-0 6-chloro-pyridazine-3-carboxylic acid butyl ester 
• 37972-69-3 6-oxo-1,6-dihydropyridazine-3-carboxylic acid 
• 63001-31-0 ethyl 1,6-dihydro-6-oxopyridazine-3-carboxylate 
• 6531-04-0 6-chloro-pyridazine-3-carbonyl chloride 
• 65202-50-8 methyl 6-chloro-3-pyridazinecarboxylate 
• 75680-92-1 6-chloro-3-pyridazinecarboxylic acid ethyl ester 

Downstream Products

• 142674-93-9 6-Benzylamino-pyridazine-3-carboxylic acid amide 
• 35857-89-7 6-chloropyridazine-3-carbonitrile 
• 187229-76-1 6-[N-(5-Chloro-2-(2-methylprop-2-en-1-yloxy)benzyl)-N-ethylamino]pyridazine-3-carboxamide 
• 177758-69-9 6-[N-(2-benzyloxy-5-bromobenzyl)-N-ethylamino]pyridazine-3-carboxamide 
• 142054-67-9 6-butylamino-3-pyridazinecarboxamide 
• 142054-70-4 6-Benzylamino-pyridazine-3-carboxylic acid methyl ester 
• 142054-71-5 6-Propylamino-pyridazine-3-carboxylic acid methyl ester 
• 49542-03-2 3-Hydrazino-6-cyano-pyridazin 
• 69579-17-5 3-[(6-carbamoyl-pyridazin-3-yl)-hydrazono]-butyric acid tert-butyl ester 
• 944808-50-8 C₁₆H₁₈ClN₅O₂ 
• 944808-49-5 N'-hydroxy-6-(4-phenoxypiperidin-1-yl)pyridazine-3-carboxamide 
• 944808-44-0 C₁₆H₁₅ClN₄O 

Relevant articles and documents

CONDENSED PYRIDINE COMPOUND

The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention. More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).

Aromatic amine compounds that antagonize the pain enhancing effects of prostaglandins

PCT No. PCT/GB96/01443 Sec. 371 Date Dec. 16, 1997 Sec. 102(e) Date Dec. 16, 1997 PCT Filed Jun. 17, 1996 PCT Pub. No. WO97/00864 PCT Pub. Date Jan. 9, 1997Compounds antagonistic of the pain enhancing effects of prostaglandins are disclosed. The compounds

Aromatic amino ethers as pain relieving agents

The present invention relates to compounds of formula (I), STR1 wherein A is an optionally substituted phenyl naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, thienyl, thiazolyl, oxazolyl, thiadiazolyl having at least two adjacent ring carbon atoms or a bicyclic ring system, provided that the --CH(R3)N(R2)B--R1 and --OCH(R4 --)--D linking groups arm positioned in a 1,2 relationship to one another on ring carbon atoms and the ring atom positioned ortho to the --OCHR4 -- linking group (and therefore in the 3-position relative to the --CHR3 NR2 -- linking group) is not substituted; B is an optionally substituted ring system; D is an optionally substituted ring system; R1 is a variety of group as defined in the description; R2 is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenylC1-3 alkyl or 5- or 6-membered heteroarylC1-3 alkyl; R3 is hydrogen or C1-4 alkyl; R4 is hydrogen or C1-4 alkyl; and N-oxides of NR2 where chemically possible; and S-oxides of sulphur containing rings were chemically possible; and pharmaceutically acceptable salts and in vivo hydrolysable esters and amides thereof. Process for their preparation, intermediates in theirpreparation, their use as therapeutic agents and pharmaceutical compositions containing them.